Johnson & Johnson: Morgan Stanley maintains a 'Equal-Weight' Rating, The Target Price is $171

Morgan Stanley maintains 'Equal-Weight' rating on Johnson & Johnson(JNJ).

The target price is $171, compare with $169 previously.

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2025-07-10	Morgan Stanley	Maintains	Equal-Weight	Equal-Weight	$171	$169

[Company Profile] Johnson & Johnson was incorporated in the State of New Jersey in 1887. Johnson & Johnson and its subsidiaries have engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company's primary focus is products related to human health and well-being. The Company is organized into two business segments: Innovative Medicine and MedTech.